Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma

Inclusion Criteria:

* Patients with vestibular schwannoma and/or meningioma diagnosed by MRI where surgical resection has been selected as treatment.
* Patients diagnosed with NF2 must meet Manchester Criteria.
* Age \> 18 years of age
* Prior biologic therapy, chemotherapy, surgery or radiation is permitted.
* At the time of screening, the patient must have normal organ and marrow function.
* Eastern Cooperative Oncology Group/World Health Organization (ECOG/WHO) performance status of 0-1.
* Patients must be able to swallow capsules.
* Patients or their legal representatives must be able to read, understand and provide informed consent to participate in the trial.
* Tumor type will be confirmed by a neuropathologist.
* Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL prior to starting AR-42.
* The patient must be willing to comply with fertility requirements

Exclusion Criteria:

* Pregnant women are excluded from this study because the potential for teratogenic or abortifacient effects of AR-42 are not known. Because there is an unknown but potential risk for AEs in nursing infants secondary to treatment of the mother with AR-42, breastfeeding should be discontinued if the mother is treated with AR-42.
* Pediatric patients are excluded from the phase 0 study as the effects of AR-42 are not known on children and there is no potential direct benefit to them.
* Patients with malabsorption or any other condition that in the opinion of the principal investigator could cause difficulty in absorption of drug.
* Patients requiring chronic corticosteroids (dose equivalent \> 20mg prednisolone).
* Concurrent use of complementary or alternative medicines that in the opinion of the principal investigator would confound the interpretation of toxicities and/or antitumor activity of the study drug.
* Patients with a "currently active" second malignancy that, in the opinion of the principal investigator, will interfere with patient participation, increase patient risk, or confound data interpretation.
* Patients with a mean QTcB \> 450 msec in males and \> 470 msec in females.
* Patients with long QT syndrome.
* Patients who are being treated for an active infection.
* Patients receiving the following concomitant medications:

  * Any other anti-neoplastic chemotherapy or biologic therapy during the study
  * Concomitant radiotherapy
  * Concomitant HDAC inhibitors (e.g. valproic acid) as class-specific adverse reactions may be additive
  * Use of granulocyte colony-stimulating factors including G-CSF, pegylated G-CSF or GM-CSF should follow ASCO guidelines for patients receiving anti-cancer therapy.
  * Drugs associated with QT/QTc prolongation (see Appendix A)
* Patients who are receiving concurrent anti-neoplastic therapy.
* Any other medical condition, including mental illness or substance abuse, deemed by the principal investigator to likely interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results.
* Patients with significant cardiovascular disease, including a myocardial infarction or unstable angina within 6 months or unstable cardiac arrhythmias are not eligible for the study.
* Known HIV infection, as their immunosuppressive conditions may complicate potential pancytopenias seen with HDAC inhibitors and complicate evaluation of drug effect.